Medios AG | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
0.30
4.50
58,220.00
133,211.00
253,636.60
Cost of Goods Sold (COGS) incl. D&A
84.40
2.20
56,693.00
132,837.00
243,234.10
Gross Income
84.00
2.30
1,527.00
374.00
10,402.50
SG&A Expense
112.60
91.70
364.00
941.00
3,145.00
EBIT
196.60
89.40
-
567.00
7,257.50
Unusual Expense
-
-
2.00
37.00
47.00
Non Operating Income/Expense
20.90
49.30
101.00
289.00
496.70
Interest Expense
-
-
-
1,292.00
96.50
Pretax Income
165.20
33.20
1,064.00
2,111.00
6,711.40
Income Tax
-
-
325.00
1,363.00
2,577.10
Consolidated Net Income
165.20
33.20
739.00
3,474.00
4,134.30
Net Income
165.20
33.20
739.00
3,171.00
4,134.30
Net Income After Extraordinaries
165.20
33.20
739.00
3,171.00
4,134.30
Net Income Available to Common
165.20
33.20
739.00
3,171.00
4,134.30
EPS (Basic)
0.37
0.07
0.83
0.73
0.32
Basic Shares Outstanding
446.30
446.30
892.50
4,351.00
12,772.00
EPS (Diluted)
0.37
0.07
0.83
0.73
0.32
Diluted Shares Outstanding
446.30
446.30
892.50
4,351.00
12,772.00
EBITDA
181.20
-
1,201.00
460.00
7,748.60
Other Operating Expense
-
0.00
-
-
-
Non-Operating Interest Income
10.60
7.00
-
-
-
Minority Interest Expense
-
-
-
303.00
-

About Medios

View Profile
Address
Friedrichstrasse 113a
Berlin Berlin 10117
Germany
Employees -
Website http://www.medios.ag
Updated 09/14/2018
Medios AG engages in providing specialty pharmaceutical drugs. These are medicines for patients with rare or chronic diseases such as cancer, HIV and hepatitis, whose personalized therapy is often tedious and cost-intensive due to their individual requirements. It operates through the following segments: Specialty Pharma Trade, Personalized Preparations, and Shared Services.